Conference Reports for NATAP

11th IAS Conference on HIV Science 18-21 July 2021 Back

Dolutegravir + 3TC at IAS 2021       IAS: SWITCHING TO THE 2-DRUG REGIMEN OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) FIXED-DOSE COMBINATION IS NON-INFERIOR TO CONTINUING A 3-DRUG REGIMEN THROUGH 48 WEEKS IN A RANDOMIZED CLINICAL TRIAL (SALSA) - (07/20/21)   IAS: METABOLIC HEALTH OUTCOMES AT WEEK 144 IN THE TANGO STUDY, COMPARING A SWITCH TO DTG/3TC VERSUS MAINTENANCE OF TAF-BASED REGIMENS - (07/20/21)   IAS: COMPARISON OF VIRAL REPLICATION FOR THE 2-DRUG REGIMEN (2DR) OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) VERSUS A 3/4-DRUG TENOFOVIR ALAFENAMIDE-BASED REGIMEN (TBR) IN THE TANGO STUDY THROUGH WEEK 96 - (07/20/21)   IAS: DTG + 3TC IN GEMINI-1 & -2: HIV-1 REPLICATION AT <50 C/ML AND VL 'BLIPS' THROUGH 144 WEEKS - (07/20/21)   IAS: FEASIBILITY, EFFICACY, AND SAFETY OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) AS A FIRST-LINE REGIMEN IN A TEST-AND-TREAT SETTING FOR NEWLY DIAGNOSED PEOPLE LIVING WITH HIV (PLWH): 48-WEEK RESULTS OF THE STAT STUDY - (07/20/21)   full IAS coverage by NATAP: 11th IAS Conference on HIV Science 18-21 July 2021   IAS: Metabolics, Comorbidities & Aging at IAS 2021 - (08/16/21)   IAS: Long-Acting Treatment & PrEP Key Studies at IAS 2021 - (08/04/21)